Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

Autor: Tuğba Başoğlu, Abdullah Sakin, Cihan Erol, Ercan Özden, Devrim Çabuk, Ebru Çılbır, Deniz Tataroğlu Özyükseler, Murat Ayhan, Mehmet Ali Şendur, Mutlu Dogan, Berna Öksüzoğlu, Melek Karakurt Eryılmaz, Özlem Er, Elif Şenocak Taşçı, Neslihan Özyurt, Özgecan Dülgar, Miraç Özen, İlhan Hacıbekiroğlu, İrem Öner, Esma Türkmen Bekmez, Hasan Çağrı Yıldırım, Şuayib Yalçın, Semra Paydaş, Emre Yekedüz, Asude Aksoy, Melike Özçelik, Abdilkerim Oyman, Elvina Almuradova, Bülent Karabulut, Nazan Demir, Murat Dinçer, Nuriye Özdemir, Dilek Erdem, Naziye Ak, Ali İnal, Derya Kıvrak Salim, Gülhan İpek Deniz, Teoman Şakalar, Ahmet Gülmez, Turgut Kaçan, Özlem Özdemir, Özkan Alan, Çağlar Ünal, Yusuf Karakaş, Serdar Turhal, Perran Fulden Yumuk
Přispěvatelé: Acibadem University Dspace, BAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., Tataroglu ozyukseler D., Ayhan M., Sendur M. A., Dogan M., et al.
Rok vydání: 2022
Předmět:
Internal Diseases
PATOLOJİ
Pharmacy
Docetaxel
Sağlık Bilimleri
Fundamental Medical Sciences
Biochemistry
BIOLOGY & BIOCHEMISTRY
İç Hastalıkları
Clinical Medicine (MED)
IMMUNOLOGY
Biyokimya
Surgery Medicine Sciences
Pathology
Biyoloji ve Biyokimya
FARMAKOLOJİ VE ECZACILIK
Klinik Tıp (MED)
Pharmacology (medical)
Patoloji
General Pharmacology
Toxicology and Pharmaceutics
Phase-Ii
Multicenter
PHARMACOLOGY & PHARMACY
Pharmacology
Toxicology and Pharmaceutics (miscellaneous)
PHARMACOLOGY & TOXICOLOGY
Klinik Tıp
Temel Bilimler
Basic Pharmaceutics Sciences
Life Sciences
Biyokimya (tıbbi)
Genel Farmakoloji
Toksikoloji ve Eczacılık
Onkoloji
Regression
Tıp
Farmakoloji (tıbbi)
Bulaşıcı hastalıklar
Oxaliplatin
Infectious Diseases
İlaç Rehberleri
Oncology
BULAŞICI HASTALIKLAR
Cerrahi Tıp Bilimleri
Farmakoloji ve Toksikoloji
Medicine
ONKOLOJİ
Folinic Acid
Fluorouracil
Natural Sciences
Histoloji
neoadjuvant chemotherapy
Histology
Farmakoloji
Temel Tıp Bilimleri
Life Sciences (LIFE)
Genel İmmünoloji ve Mikrobiyoloji
Pathology and Forensic Medicine
Drug Guides
Yaşam Bilimleri
Health Sciences
Perioperative Chemotherapy
Farmakoloji
Toksikoloji ve Eczacılık (çeşitli)
Eczacılık
Pharmacology
Internal Medicine Sciences
İmmünoloji
General Immunology and Microbiology
gastroesophageal junction cancer
Biochemistry (medical)
Dahili Tıp Bilimleri
CLINICAL MEDICINE
Pharmacology and Therapeutics
Temel Eczacılık Bilimleri
Yaşam Bilimleri (LIFE)
Surgery
Cisplatin
Gastric cancer
Patoloji ve Adli Tıp
Zdroj: Journal of Chemotherapy. 35:142-149
ISSN: 1973-9478
1120-009X
DOI: 10.1080/1120009x.2022.2073159
Popis: Neoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare the efficacy and toxicity profile of different chemotherapy regimens in our country. This retrospective multicentre study included locally advanced GC and GEJ cancer patients who received NACT between 2007 and 2021. Relation between CT regimens and pathological evaluation were analysed. A total of 794 patients from 45 oncology centers in Turkey were included. Median age at the time of diagnosis was 60 (range: 18-86). Most frequent NACT regimens used were FLOT (65.4\%), DCF (17.4\%) and ECF (8.1\%), respectively. In the total study group, pathological complete remission (pCR) rate was 7.2\%, R0 resection rate 86.4\%, and D2 dissection rate was 66.8\%. Rate of pCR and near-CR (24\%), and R0 resection (84\%) were numerically higher in FLOT arm (p > 0.05). Patients who received FLOT had also higher chemotherapy-related toxicity rate compared to patients who received other regimens (p > 0.05). Median follow-up time was 16 months (range: 1-154 months). Estimated median overall survival (OS) was 58.4months (95\% CI: 35.2-85.7) and disease-free survival (DFS) was 50.7 months (95\% CI: 25.4-75.9). The highest 3-year estimated OS rate was also shown in FLOT arm (68\%). We still do not know which NACT regimen is the best choice for daily practice. Clinicians should tailor treatment regimens according to patients' multifactorial status and comorbidities for to obtain best outcomes. Longer follow-up period needs to validate our results.
Databáze: OpenAIRE
Externí odkaz: